false 0001770787 0001770787 2022-07-14 2022-07-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 12, 2022
10x Genomics, Inc.
(Exact name of registrant as specified in its charter)

Delaware | 001-39035 | 45-5614458
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)

6230 Stoneridge Mall Road
Pleasanton, California 94588
(925) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol |  | Name of each exchange on which registered
Class A common stock, par value $0.00001 per share |  | TXG |  | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.
On July 14, 2022, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s preliminary second quarter revenue for the period ended June 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On July 12, 2022, the Company hired James Wilbur, Ph.D., as Chief Commercial Officer of the Company, effective July 27, 2022.
On July 14, 2022, the Company issued a press release announcing Dr. Wilbur's hiring as Chief Commercial Officer. A copy of such press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
As previously disclosed, the Company's outgoing Chief Commercial Officer, Brad Crutchfield, will continue to provide transition services to the Company through December 31, 2022 unless Mr. Crutchfield's employment is terminated prior to such time.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.

Exhibit No. |  | Description of Exhibits |
99.1 |  | Press Release dated July 14, 2022. |
99.2 |  | Press Release dated July 14, 2022. |
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| 10x Genomics, Inc.
| By: | /s/ Eric S. Whitaker
| Name: | Eric S. Whitaker
| Title: | Chief Legal Officer
Date: July 14, 2022 |  |